Eli Lilly’s Obesity Drug Will Be the Focus of Earnings

Drugmaker Eli Lilly will give investors a first glimpse at sales figures for Zepbound, its new obesity medicine, on Tuesday when it releases its fourth-quarter earnings results. Sales of Mounjaro, the diabetes treatment approved in 2022 that is the same medicine as Zepbound, are expected to have hit $1.7 billion for the quarter, up from $279 million for the same quarter in 2022. Lilly shares have been on a tear, due largely to excitement over the sales potential of Zepbound and Mounjaro.